证券日报网讯2月3日，赛分科技在互动平台回答投资者提问时表示，公司是全球范围内少数同时具备分 析色谱及工业纯化的先进研发及规模化生产能力的企业之一，是国内竞争中的主要参与者。公司依托自 主可控的工艺平台、行业领先的技术实力与卓越的产品表现，与国内生物医药行业各细分领域的领军企 业建立了色谱填料长期合作关系。未来，伴随下游医药行业市场规模持续扩容、国产替代进程加速推 进，叠加公司海外业务的稳步拓展，公司的市场占有率将进一步提升。 ...

Core Insights - The company, Saifen Technology, specializes in chromatography columns and packing materials used for the analysis and purification of biopharmaceuticals and small molecule drugs, which are essential throughout the drug development process [2] - Saifen Technology has over 5,000 cumulative customers globally, including clients from several EU member states, indicating a broad market presence [2] - The company's revenue from the EU region is relatively small, primarily generated through direct sales by its US subsidiary or through distributors [2]

Core Viewpoint - Nanwei Technology announced its 2025 performance forecast, expecting a net profit attributable to the parent company of between 128 million to 145 million yuan, representing a growth of 54.51% to 75.03% compared to the previous year [1] Group 1: Financial Performance - The projected net profit for 2025 is between 128 million to 145 million yuan [1] - This represents a significant increase of 54.51% to 75.03% year-over-year [1] Group 2: Business Strategy and Growth - The company is implementing a "3+2" market development strategy [1] - Core product innovation and quality improvements are driving rapid sales growth in chromatography fillers, chromatography media, and liquid chromatography columns [1] - International business expansion has shown significant results, with overseas revenue increasing by approximately 79% year-over-year [1]

Core Insights - The article highlights the significant role of upstream materials, specifically "solid-phase synthesis carriers" and "chromatography fillers," in the production of GLP-1 peptide drugs, with Blue Sky Technology (蓝晓科技) being a key player in this sector [1][2] - The company has shown strong diversified growth, with its life sciences segment becoming a primary growth engine, expanding from traditional raw material purification to include critical materials for peptide and nucleic acid drug synthesis [1][11] Company Overview - Blue Sky Technology is recognized as a major innovator in the upstream materials field, providing solutions for industrial separation and purification challenges across various sectors, including life sciences and lithium extraction [1][3] - The company has established a unique growth logic by redefining the performance boundaries of upstream materials, thereby reshaping downstream industry cost curves and research possibilities [2] Technology and Innovation - The company focuses on enhancing its core competitiveness in adsorption separation technology, which has evolved from general applications to high-precision separation demands in various industries [3][4] - Blue Sky Technology invests approximately 6% of its annual revenue into R&D, operating five pilot workshops to ensure the industrialization of 4 to 8 new products and 6 to 10 new processes each year [6][11] Life Sciences Segment - The life sciences segment has rapidly grown, particularly in the solid-phase synthesis carrier field, where the company has become a key supplier for GLP-1 peptide drugs [7][11] - The company is expanding its product offerings to include solid-phase synthesis carriers and chromatography fillers for nucleic acid drugs, addressing the unique requirements of different drug types [10][12] Strategic Development - Blue Sky Technology plans to invest 1.15 billion yuan in a new life sciences industrial park, which will include a 1,000 square meter pilot laboratory and a 2,000 square meter facility, adhering to GMP standards [11] - The company is also establishing a subsidiary in Sweden and recruiting industry experts to enhance collaboration with leading pharmaceutical companies [11][12]

Core Viewpoint - The construction ceremony for the 200,000 liters/year biopharmaceutical separation and purification auxiliary materials project by Suzhou Saifen Technology Co., Ltd. was held, marking a significant milestone in the company's expansion and capacity enhancement in the biopharmaceutical sector [1]. Group 1: Project Details - The project will include the construction of three chromatography medium production workshops, along with supporting warehouses, tank areas, and wastewater treatment facilities, covering an area of approximately 21,000 square meters [1]. - The new project will add an annual production capacity of 200,000 liters of chromatography media, including affinity chromatography fillers, ion exchange fillers, and composite chromatography fillers [1]. Group 2: Company Performance - Saifen Technology has been actively involved in the rapid development of China's biopharmaceutical industry, accumulating over 100 application projects in various biopharmaceutical segments, including antibodies and insulin [2]. - The company reported a strong business performance since its listing on the STAR Market, achieving a revenue of 302 million yuan in the first three quarters of 2025, a year-on-year increase of 38.39%, and a net profit of 93.21 million yuan, up 71.07% [3]. Group 3: Market Context - The rapid development of the Chinese biopharmaceutical industry is highlighted by significant achievements from partners of Saifen Technology, indicating a growing demand for high-performance, large-scale, and high-quality domestic chromatography fillers [4]. - The new project will enhance the company's ability to deliver on a large scale and support the stable production and capacity growth of its partners, while also aiding in the company's strategy to expand into overseas markets [4].

Core Viewpoint - Nanwei Technology is progressing according to its operational plans, with core business development performing well since its listing in 2021, and the actual controller, Dr. Jiang Biwang, has not executed any share reduction actions [1] Group 1: Business Development - The company focuses on separation purification and analytical testing as its main business, continuously consolidating its competitive advantage through technological innovation and quality improvement [1] - Nanwei Technology has successfully built a "chromatography full ecological platform" that includes products such as chromatography fillers, chromatography analysis columns, separation/analysis equipment, and solvent-resistant membrane systems [1] Group 2: Future Growth and Innovation - The company is making ongoing investments in the horizontal expansion of high-performance microsphere materials, aiming for innovative breakthroughs and domestic substitution in more microsphere application fields [1] - The goal is to cultivate new business growth points through these innovations [1]

Core Viewpoint - GLP-1 related business is a significant growth driver for the company's life sciences segment, with a focus on market share and collaboration with major clients [1] Group 1: Market Position and Revenue - The company maintains a market share of over 70% for GLP-1 peptide solid-phase synthesis carriers in the domestic clinical pipeline [1] - In the first half of 2025, the company's revenue from the life sciences sector reached 320 million yuan [1] Group 2: Product Range and Client Base - The company offers a diverse range of products in the life sciences field, including solid-phase synthesis carriers for peptides, small nucleic acid synthesis carriers, chromatography fillers, chromatography media, and enzyme carriers [1] - The main downstream customers for the company's peptide solid-phase synthesis carriers are CDMO enterprises, although specific sales revenue and client information for each product type have not been disclosed [1] Group 3: Collaboration with Major Clients - The company is in collaboration with leading clients such as Eli Lilly and Novo Nordisk, focusing on long-term supply agreements and product delivery schedules [1]

Industry Rating - The industry investment rating is maintained as "Outperform" [1] Core Views - The domestic demand for the research service sector is recovering, supported by national policies and increased market activity in innovative drugs, leading to stable revenue and profit growth [2][6] - The overseas business environment is showing steady recovery, with domestic companies making significant progress in international markets, enhancing their profit margins [3][19] - The overall performance of the research service sector is improving, with a notable increase in both domestic and overseas business contributions [6][41] Summary by Sections Financial Performance - For the first three quarters of 2025, the overall revenue of the research service sector increased by 6.61% year-on-year, with net profit rising by 13.30% and non-recurring net profit up by 20.89% [5][6] - In Q3 2025 alone, the sector's revenue grew by 8.53% year-on-year, with net profit increasing by 17.97% and non-recurring net profit by 36.37% [6] - The gross profit margin for the sector was 49.95%, reflecting a 1.64 percentage point increase year-on-year, attributed to improved product quality and effective cost control [6] Market Trends - The demand for innovative drug research is driving growth in the sector, with a significant increase in the number of projects and investments in high-value services [2][14] - The trend of domestic companies replacing imported products is gaining momentum, with leading firms expected to capture a larger market share [2][7] Company Recommendations - Companies to watch include Haoyuan Pharmaceutical, Baiao Saitou-H, Naimi Technology, Aopumai, Yaokang Biological, and Saifen Technology, which are likely to benefit from improved industry demand [4] - New business opportunities are emerging for Haoyuan Pharmaceutical and Baiao Saitou-H, particularly in ADC CDMO services [4][27] Segment Performance - The research service sector consists of 18 listed companies, with stable growth across various segments, including model animals, biological reagents, and chromatography materials [6][7] - Companies like Naimi Technology and Yaokang Biological are experiencing significant growth in their respective fields, driven by strong domestic and international demand [30][36]

Summary of the Conference Call for Sifang Technology Company Overview - **Company**: Sifang Technology - **Industry**: Industrial Purification and Chromatography Key Financial Metrics - **Revenue**: - Q3 2025 revenue reached 3.02 billion CNY, a year-on-year increase of 38.39% [3] - Industrial purification segment revenue was 1.208 billion CNY, up 68.08% year-on-year, accounting for 69% of total revenue [2][3] - Net profit attributable to shareholders was 93.21 million CNY, a 71.07% increase year-on-year [2][3] - **Gross Margin**: - Overall gross margin for Q3 2025 was 72.73% [3] Segment Performance - **Industrial Purification Segment**: - Antibody drugs accounted for 60.62% of revenue, with a total of 1.26 billion CNY [5] - GLP-1 insulin peptide segment revenue grew by 161.44%, contributing 35.41% of the segment [5] - Revenue from recombinant proteins decreased significantly [5] - **Commercialization Stage**: - Revenue from commercialized products was approximately 122.3 million CNY, contributing nearly 60% of purification business revenue [9] - Late-stage clinical and commercialization revenue accounted for about 77% of total industrial purification revenue [9] Project Pipeline and Development - **Project Count**: - As of September 30, 2025, the company had 1,126 projects, with 893 in R&D, 170 in clinical stages, and 60 in commercialization [2][6] - In Q3 2025, 75 new projects were added, with 57 in R&D, 14 in clinical, and 4 in commercialization [6] - **Future Expectations**: - Anticipation of significant orders from clinical phase III projects entering commercialization in 2026, including recombinant proteins and antibodies [4][11] Market Dynamics - **Pricing Trends**: - Domestic chromatography media prices are 40%-50% of imported prices, with expectations of further price reductions in 2026 [7] - The company maintains a gross margin of around 70% for chromatography media [7] - **Customer Demand**: - Increasing number of phase I and II clinical projects, with 137 projects cumulatively [10] - The company has established strong relationships with major clients in the blood products sector, including significant projects in clinical phases [21] International Expansion - **Overseas Market Growth**: - Revenue from overseas markets grew over 300% year-on-year [14] - Plans to establish a factory in Delaware, USA, to support expansion into the North American market [12][13][15] - **Market Strategy**: - Differentiated strategies for the US and "Belt and Road" countries, focusing on technology in the US and competitive pricing in other regions [14] Future Capacity and Revenue Potential - **Capacity Expansion**: - Plans for a 200,000-liter production capacity in Yangzhou and a 50,000-liter facility in the US, with potential annual revenue of approximately 30 billion CNY if fully utilized [23] - **Market Size**: - The global market for related products is estimated to be in the hundreds of billions of CNY, indicating significant growth potential [17] Conclusion - **Overall Outlook**: - The company is positioned for substantial growth with a robust project pipeline, strong market demand, and strategic international expansion plans. The focus on maintaining stable pricing and high-quality products will support long-term profitability and market leadership.

Group 1: Industry Overview - The pharmaceutical and biotechnology industry is entering a new upward cycle, with accelerated overseas orders and strong upward momentum, particularly for companies with strong overseas capabilities in the upstream biological sector [1] - The early-stage CRO (Contract Research Organization) industry is experiencing a significant development opportunity, driven by the historical chance for innovative drugs to expand internationally [1] Group 2: Early-stage CRO - The early-stage CRO industry is seeing a shift towards domestic advantages in quality, efficiency, and cost, as overseas demand for early-stage research increases [1] - The demand for preclinical and safety evaluation orders is gradually recovering, with a recommendation to focus on leading companies such as Yino Science and Zhaoyan New Drug [1] - The supply-demand mismatch for experimental monkeys is expected to persist, leading to stable prices in the short term [1] Group 3: Upstream Biological Products - The domestic biological sector is recovering quickly, with significant growth expected in biological reagents, including culture media and recombinant proteins, driven by the structural recovery from domestic innovative drug exports [2] - The overseas market presents vast opportunities, and domestic brands are favored for their cost-effectiveness, suggesting a focus on companies with overseas capabilities such as Baipusais and Haoyuan Pharmaceutical [2] Group 4: Clinical CRO - The clinical CRO sector is approaching a turning point, with SMO (Site Management Organization) orders showing early signs of recovery [3] - As innovative drug financing improves, the number of clinical projects is expected to increase, leading to a recovery in overall orders [3] - Leading clinical CRO companies such as Tigermed and Nossger are recommended for investment [3] Group 5: CDMO - The CDMO (Contract Development and Manufacturing Organization) sector is showing strong performance, particularly in the peptide and ADC (Antibody-Drug Conjugate) segments, which are expected to maintain high growth rates [4] - New molecular tracks, including small nucleic acids, also present significant long-term development potential [4] - Recommended CDMO leaders include Kelaiying and WuXi AppTec, which are expected to show performance elasticity due to stable small molecule business and rapid growth in new molecular business [4]